These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18753117)

  • 1. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.
    Simpson KN; Roberts G; Hicks CB; Finnern HW
    HIV Clin Trials; 2008; 9(4):225-37. PubMed ID: 18753117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.
    Hubben GA; Bos JM; Veltman-Starkenburg CA; Stegmeijer S; Finnern HW; Kappelhoff BS; Simpson KN; Tramarin A; Postma MJ
    Cost Eff Resour Alloc; 2007 Nov; 5():15. PubMed ID: 18034881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipranavir: a ritonavir-boosted protease inhibitor.
    Croom KF; Keam SJ
    Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
    Allavena C; Flandre P; Pugliese P; Valantin MA; Poizot-Martin I; Cabié A; Melliez H; Cuzin L; Duvivier C; Dellamonica P; Raffi F;
    Scand J Infect Dis; 2012 Jan; 44(1):37-43. PubMed ID: 21851330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens.
    Huang IC; Wu AW; Finnern HW; Thijs H; Gathe JC; Fairclough DL
    Antivir Ther; 2008; 13(1):15-25. PubMed ID: 18389895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.